See more : Barclays PLC (BCS) Income Statement Analysis – Financial Results
Complete financial analysis of Verrica Pharmaceuticals Inc. (VRCA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Verrica Pharmaceuticals Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Litian Pictures Holdings Limited (9958.HK) Income Statement Analysis – Financial Results
- Investeringsforeningen Bankinvest – Amerikanske Aktier Indeks Kl (BAIBUU.CO) Income Statement Analysis – Financial Results
- Visagar Polytex Limited (VIVIDHA.BO) Income Statement Analysis – Financial Results
- Advice Capital Globale (ACIGLO.CO) Income Statement Analysis – Financial Results
- Siward Crystal Technology Co., Ltd (2484.TW) Income Statement Analysis – Financial Results
Verrica Pharmaceuticals Inc. (VRCA)
About Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatological oncology indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 5.12M | 9.03M | 12.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 746.00K | 725.00K | 472.00K | 229.00K | 257.20K | 20.29K | 0.00 | 0.00 |
| Gross Profit | 4.38M | 8.31M | 11.53M | -229.00K | -257.20K | -20.29K | 0.00 | 0.00 |
| Gross Profit Ratio | 85.44% | 91.97% | 96.07% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 20.30M | 12.20M | 15.93M | 15.67M | 15.44M | 12.83M | 3.73M | 1.71M |
| General & Administrative | 0.00 | 17.41M | 26.98M | 24.51M | 14.64M | 9.05M | 727.00K | 204.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 47.31M | 17.41M | 26.98M | 24.51M | 14.64M | 9.05M | 727.00K | 204.00K |
| Other Expenses | 2.54M | -58.00K | 0.00 | -1.00K | 1.87M | -1.00K | 0.00 | 0.00 |
| Operating Expenses | 70.14M | 29.60M | 42.91M | 40.18M | 30.08M | 21.88M | 4.46M | 1.91M |
| Cost & Expenses | 70.88M | 30.33M | 42.91M | 40.18M | 30.08M | 21.88M | 4.46M | 1.91M |
| Interest Income | 2.74M | 476.00K | 123.00K | 521.00K | 1.88M | 1.23M | 0.00 | 0.00 |
| Interest Expense | 3.96M | 2.17M | 4.30M | 3.03M | 0.00 | 0.00 | 2.00K | 0.00 |
| Depreciation & Amortization | 836.00K | 718.00K | 472.00K | 229.00K | 257.20K | 20.29K | 4.46M | 1.91M |
| EBITDA | -62.20M | -21.60M | -30.31M | -39.43M | -30.08M | -20.63M | -4.46M | -1.91M |
| EBITDA Ratio | -1,213.84% | -231.16% | -256.54% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -65.76M | -21.30M | -30.91M | -40.18M | -30.08M | -21.88M | -4.46M | -1.91M |
| Operating Income Ratio | -1,283.35% | -235.78% | -257.57% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -1.24M | -3.19M | -4.17M | -2.51M | 1.87M | 1.23M | -2.00K | 0.00 |
| Income Before Tax | -67.00M | -24.49M | -35.08M | -42.69M | -28.21M | -20.65M | -4.46M | -1.91M |
| Income Before Tax Ratio | -1,307.47% | -271.11% | -292.33% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 3.19M | 3.82M | 2.80M | -257.00K | 1.23M | -4.46M | -1.91M |
| Net Income | -67.00M | -27.68M | -38.90M | -45.50M | -27.95M | -20.65M | -4.46M | -1.91M |
| Net Income Ratio | -1,307.47% | -306.44% | -324.19% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.48 | -0.81 | -1.44 | -1.82 | -1.12 | -1.41 | -0.22 | -0.10 |
| EPS Diluted | -1.48 | -0.81 | -1.44 | -1.82 | -1.12 | -1.41 | -0.22 | -0.10 |
| Weighted Avg Shares Out | 45.34M | 34.16M | 27.04M | 25.00M | 24.90M | 14.66M | 19.95M | 19.95M |
| Weighted Avg Shares Out (Dil) | 45.34M | 34.16M | 27.04M | 25.00M | 24.90M | 14.66M | 19.95M | 19.95M |
Verrica Pharmaceuticals Inc. (VRCA) Q3 2023 Earnings Call Transcript
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA ) Q3 2023 Earnings Conference Call November 9, 2023 8:30 AM ET Company Participants Kevin Gardner - LifeSci Advisors Ted White - President & Chief Executive Officer\ Joe Bonaccorso - Chief Commercial Officer Terry Kohler -...
Verrica Pharmaceuticals Reports Third Quarter 2023 Financial Results
– Strong awareness and interest in prescribing YCANTH™ among dermatologists and pediatricians – – Over 112 million lives covered to date on commercial insurance and managed Medicaid plans – – Conference Call Scheduled for Today at 8:30 am ET – WEST...
Verrica Pharmaceuticals to Provide a Corporate Update and Report Third Quarter Financial Results on November 9, 2023
WEST CHESTER, Pa., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and...
Verrica Pharmaceuticals to Host Virtual KOL Event Discussing the Approval of YCANTH™ (Cantharidin) Topical Solution for the Treatment of Molluscum on October 11, 2023
WEST CHESTER, Pa., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a virtual KOL event...
Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright 25th Annual Global Investment Conference
WEST CHESTER, Pa., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that that Ted White, Verrica President and CEO,...
Verrica Pharmaceuticals Announces First Sale of YCANTH™ to FFF Enterprises
YCANTH™ is the first and only FDA-approved treatment for molluscum, a highly contagious viral skin infection affecting approximately 6 million people annually in the United States, primarily children
Verrica Issues Statement in Support of FDA's Warning Letters to Manufacturers and Retailers for Producing and Selling Unapproved Products for the Treatment of Molluscum Contagiosum
Verrica's product YCANTH™ is the first and only FDA-approved treatment for molluscum, a highly contagious viral skin infection affecting approximately 6 million people annually in the United States, primarily children
Verrica Pharmaceuticals Announces Presentation of Lesion Clearance Data from an Ongoing Phase 2 Study of VP-315 for the Treatment of Basal Cell Carcinoma at the American Academy of Dermatology (AAD) 2023 Innovation Academy Meeting
Presentation highlights the antitumor response of VP-315 for the non-surgical treatment of Basal Cell Carcinoma (BCC) as determined by clinical and histological lesion clearance
Verrica Pharmaceuticals Reports Second Quarter 2023 Financial Results
– In July, FDA approved YCANTH™ for the treatment of molluscum, a highly contagious viral skin infection affecting approximately 6 million people annually in the United States, primarily children –
Verrica Pharmaceuticals Announces Acceptance of Abstract Featuring Clinical Data of VP-315 for the Treatment of Basal Cell Carcinoma at the American Academy of Dermatology Association's (AAD) 2023 Innovation Academy Meeting
Presentation to highlight the antitumor efficacy of VP-315 for the Treatment of Basal Cell Carcinoma (BCC) as determined by clinical and histological lesion clearance Presentation to highlight the antitumor efficacy of VP-315 for the Treatment of Basal Cell Carcinoma (BCC)...
Source: https://incomestatements.info
Category: Stock Reports